Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
3019 participants
INTERVENTIONAL
2017-08-30
2019-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults
NCT03732638
An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine
NCT03934086
Safety and Efficacy Study in Adult Subjects With Acute Migraines
NCT03235479
Safety and Efficacy in Adult Subjects With Acute Migraines
NCT03237845
Trial in Adult Subjects With Acute Migraines
NCT03461757
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Rimegepant
Rimegepant
75 mg oral tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rimegepant
75 mg oral tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age of onset of migraines prior to 50 years of age
* Migraine attacks, on average, lasting 4-72 hours if untreated
* Ability to distinguish migraine attacks from tension/cluster headaches
* Patients with contraindications for use of triptans may be included provided they meet all other study entry criteria
Exclusion Criteria
* History of HIV disease
* History with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia.
* Uncontrolled hypertension or uncontrolled diabetes (however, patients can be included who have stable hypertension and /or diabetes for 3 months prior to screening
* History of gastric or small intestinal surgery or has a disease that causes malabsorption
* BMI ≥ 30
* HbA1c ≥ 6.5%
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Research Associates, Inc
Birmingham, Alabama, United States
Coastal Clinical Research, Inc.
Mobile, Alabama, United States
Thunderbird Internal Medicine / Radiant Research, Inc
Glendale, Arizona, United States
Neurological Physicians of Arizona
Tempe, Arizona, United States
Clinical Research Consortium Arizona
Tempe, Arizona, United States
Woodland International Research Group, LLC
Little Rock, Arkansas, United States
Woodland Research Northwest, LLC
Rogers, Arkansas, United States
Pharmacology Research Institute
Encino, California, United States
eStudySite
La Mesa, California, United States
Collaborative Neuroscience Network, LLC
Long Beach, California, United States
Pharmacology Research Institute
Los Alamitos, California, United States
Pharmacology Research Institute
Newport Beach, California, United States
Pacific Research Partners LLC
Oakland, California, United States
National Research Institute
Panorama City, California, United States
Optimus Medical Group
San Francisco, California, United States
California Medical Clinic for Headache
Santa Monica, California, United States
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California, United States
Diablo Clinical Research, Inc
Walnut Creek, California, United States
Clinical Trials of the Rockies
Denver, Colorado, United States
AGA Clinical Trials
Hialeah, Florida, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
Multi-Specialty Research Associates, Inc
Lake City, Florida, United States
Renstar Medical Research
Ocala, Florida, United States
Clinical Neuroscience Solutions, Inc
Orlando, Florida, United States
Compass Research, LLC
Orlando, Florida, United States
Ormond Medical Arts Pharmaceutical Research
Ormond Beach, Florida, United States
Meridien Research
Tampa, Florida, United States
Radiant Research, Inc.
Atlanta, Georgia, United States
Meridian Clinical Research
Savannah, Georgia, United States
Savannah Neurology Specialists
Savannah, Georgia, United States
Christie Clinic, LLC
Champaign, Illinois, United States
PMG Research of McFrland Clinic
Ames, Iowa, United States
Heartland Research Associates, LLC
Augusta, Kansas, United States
Heartland Research Associates, LLC
Newton, Kansas, United States
Heartland Research Associates, LLC
Wichita, Kansas, United States
Heartland Research Associates, LLC
Wichita, Kansas, United States
Benchmark Research
Metairie, Louisiana, United States
MedPharmics, LLC
Metairie, Louisiana, United States
New Orleans Center for Clinical Research
New Orleans, Louisiana, United States
Boston Clinical Trials, Inc.
Boston, Massachusetts, United States
NECCR Primacare Research, LLC
Fall River, Massachusetts, United States
Milford Emergency Associates, Inc.
Marlborough, Massachusetts, United States
Michigan Head Pain and Neurological Institute
Ann Arbor, Michigan, United States
Clinical Research Institute, Inc.
Minneapolis, Minnesota, United States
Clinical Research Insitute
Plymouth, Minnesota, United States
The Center for Pharmaceutical Research
Kansas City, Missouri, United States
Sundance Clinical Research, LLC
St Louis, Missouri, United States
Meridian Clinical Research -Norfolk
Norfolk, Nebraska, United States
Meridian Clinical Research, LLC
Omaha, Nebraska, United States
Clinical Research Consortium- Las Vegas
Las Vegas, Nevada, United States
Hassman Research Institute, LLC
Berlin, New Jersey, United States
Albuquerque Neuroscience, Inc.
Albuquerque, New Mexico, United States
United Medical Associates
Binghamton, New York, United States
SPRI Clinical Trials, LLC
Brooklyn, New York, United States
Regional Clinical Research, Inc.
Endwell, New York, United States
Radiant Research, Inc.
Jamaica, New York, United States
Central New York Clinical Research
Manlius, New York, United States
Fieve Clinical Research
New York, New York, United States
Rochester Clinical Research, Inc
Rochester, New York, United States
Montefiore Heachache Center
The Bronx, New York, United States
PMG Research of Charlotte, LLC
Charlotte, North Carolina, United States
PharmQuest, LLC
Greensboro, North Carolina, United States
PMG Research of Raleigh, LLC
Raleigh, North Carolina, United States
Wake Research Associates, LLC
Raleigh, North Carolina, United States
PMG Research of Wilmington, LLC
Wilmington, North Carolina, United States
CTI Clinical Research Center
Cincinnati, Ohio, United States
Radiant Research, Inc.
Cincinnati, Ohio, United States
Radiant Research, Inc.
Columbus, Ohio, United States
Midwest Clinical Research Center
Dayton, Ohio, United States
Neurology Diagnostics, Inc.
Dayton, Ohio, United States
Aventiv Research, Inc.
Dublin, Ohio, United States
Summit Research Network (Oregon), Inc.
Portland, Oregon, United States
Oregon Center for Clinical Investigations, Inc
Salem, Oregon, United States
Clinical Research of Philadelphia, LLC
Philadelphia, Pennsylvania, United States
Fieve Clinical Research
Scranton, Pennsylvania, United States
Preferred Primary Care Physicians
Uniontown, Pennsylvania, United States
Omega Medical Research
Warwick, Rhode Island, United States
Radiant Research, Inc.
Anderson, South Carolina, United States
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States
Meridian Clinical Research
Dakota Dunes, South Dakota, United States
PMG Research of Bristol, LLC
Bristol, Tennessee, United States
Clinical Neuroscience Solutions, Inc
Memphis, Tennessee, United States
Clinical Research Associates, Inc.
Nashville, Tennessee, United States
FutureSearch Trials of Neurology, LP
Austin, Texas, United States
Tekton Research- Austin
Austin, Texas, United States
FutureSearch Trials of Neurology, LP
Dallas, Texas, United States
Ventavia Research Group, LLC
Fort Worth, Texas, United States
Texas Center for Drug Development
Houston, Texas, United States
Red Star Research, LLC
Lake Jackson, Texas, United States
FMC Science
Lampasas, Texas, United States
PCP for Life
Magnolia, Texas, United States
Research Across America - Mesquite
Mesquite, Texas, United States
Doctors of Internal Medicine, LTD / Radiant Research Inc.
Plano, Texas, United States
DM Clinical Research
Tomball, Texas, United States
J.Lewis Research Inc / Foothill Family Clinic South
Salt Lake City, Utah, United States
Tidewater Integrated Medical Research
Virginia Beach, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Seattle Women's:Health, Research & Gynecology
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ailani J, Pavlovic J, Pixton GC, Fullerton T. Rimegepant safety and patient-reported outcomes among triptan-naive, triptan-using, and triptan-failure participants: Subgroup analysis of an open-label, multicenter study. Cephalalgia. 2025 Jul;45(7):3331024251343309. doi: 10.1177/03331024251343309. Epub 2025 Jul 9.
Kudrow D, Hutchinson S, Pixton GC, Fullerton T. Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study. Pain Ther. 2025 Feb;14(1):237-255. doi: 10.1007/s40122-024-00675-6. Epub 2024 Nov 9.
True D, Mullin K, Croop R. Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study. Pain Ther. 2024 Oct;13(5):1203-1218. doi: 10.1007/s40122-024-00626-1. Epub 2024 Jul 10.
Fullerton T, Pixton G. Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics. J Pain Res. 2024 May 15;17:1751-1760. doi: 10.2147/JPR.S456006. eCollection 2024.
Croop R, Berman G, Kudrow D, Mullin K, Thiry A, Lovegren M, L'Italien G, Lipton RB. A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia. 2024 Apr;44(4):3331024241232944. doi: 10.1177/03331024241232944.
Johnston K, Harris L, Powell L, Popoff E, Coric V, L'Italien G, Schreiber CP. Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000-201). J Headache Pain. 2022 Jan 17;23(1):10. doi: 10.1186/s10194-021-01378-5.
Johnston KM, L'Italien G, Popoff E, Powell L, Croop R, Thiry A, Harris L, Coric V, Lipton RB. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant. Adv Ther. 2021 Oct;38(10):5209-5220. doi: 10.1007/s12325-021-01897-2. Epub 2021 Aug 29.
Mullin K, Kudrow D, Croop R, Lovegren M, Conway CM, Coric V, Lipton RB. Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology. 2020 May 19;94(20):e2121-e2125. doi: 10.1212/WNL.0000000000008944. Epub 2020 Jan 13.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BHV3000-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.